December 2022
Volume 22, Issue 14
Open Access
Vision Sciences Society Annual Meeting Abstract  |   December 2022
A novel eye-tracking-based binocular therapeutic improves visual performances in amblyopic children: a pilot study.
Author Affiliations
  • Oren Yehezkel
    NovaSight LTD., Airport City, Israel
  • Tamara Wygnanski-Jaffe
    Goldschleger Eye Institute, Tel-Hashomer, Israel.
    Sackler Faculty of Medicine, Tel- Aviv University, Tel-Aviv, Israel
  • Michael Belkin
    Goldschleger Eye Institute, Tel-Hashomer, Israel.
    Sackler Faculty of Medicine, Tel- Aviv University, Tel-Aviv, Israel
  • Avital Moshkovitz
    NovaSight LTD., Airport City, Israel
    Bar-Ilan University. Ramat Gan, Israel
Journal of Vision December 2022, Vol.22, 4497. doi:https://doi.org/10.1167/jov.22.14.4497
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Oren Yehezkel, Tamara Wygnanski-Jaffe, Michael Belkin, Avital Moshkovitz; A novel eye-tracking-based binocular therapeutic improves visual performances in amblyopic children: a pilot study.. Journal of Vision 2022;22(14):4497. https://doi.org/10.1167/jov.22.14.4497.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Introduction: A study was conducted to evaluate the safety and effectiveness of a novel treatment for amblyopia using a binocular- eye-tracking- based device (CureSight). Methods: 20 children aged 4-16 (8.08 ±3.2 years) with anisometropic, strabismic or mixed amblyopia watched a movie of their choice five times a week for 90 minutes over three months, followed by three weekly sessions for additional three months. An eye tracker with a sampling rate of 90 Hz was used to identify the gaze position of each eye. Dichoptic movies were presented with the foveal area of the non-amblyopic eye blurred to visual acuity two lines below the acuity of the amblyopic eye. Best-corrected visual acuity (BCVA) at near and distance, stereo acuity, and reading performance were assessed. Six months of follow-up. Results: The mean compliance with treatment dosage was 95%. BCVA improved by 3.34 ±0.05 ETDRS lines for near (95% CI, 0.235-0.375; P<0.005) and by 1.8 ±0.04 for distance (95% CI, 0.145-0.257; P<0.005). Binocular VA improved by 1.1 ± 0.04 and 0.13 ± 0.03 lines for near and distance (P<0.01; paired t-test). The mean stereoacuity improved from 285 ± 66 to 73 ±14 arcsec (3-octave steps 95% CI, 105-292; P <0.005). Reading speed improved by an average of 40%. No adverse effects were reported. Two children reported difficulty adhering to the study protocol. Conclusion/relevance: Subjects significantly improved VA of the amblyopic eye, stereo acuity, and reading speed. Improvement of binocular VA indicates a reduction in intraocular suppression. The tested Curesight system is a potentially effective home treatment for amblyopia, with high compliance and no difficulty in fitting or calibration, with a year of follow-up.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×